Fig. 8
CA2-2-treated M1 macrophages exhibit antitumor activity. in vivo. (A) Survival of mice with Ehrlich ascites carcinoma (2 × 106 cells/mouse) in groups receiving cell therapy with peritoneal macrophages and peritoneal macrophages pre-treated with CA2-2 (0.02 µM, 2 h) administered intraperitoneally at a concentration of 1 × 105 cells/mouse at 1, 3, and 7 days after tumor inoculation. Increase in life span (ILS) of mice receiving M1 macrophages in expressed in %. (B) Representative image of mice with ascite Ehrlich carcinoma on 20 day of experiment in control group (left) and after injection with CA2-2-treated M1 macrophages. (C) Effect of activated primary macrophages on the nude mouse bearing 4T1 breast cancer. (D) Change in tumor size. The tumor increasing volume of different groups. (E) Representative image of mice with 4T1 tumor on 15 day of experiment in control group (left) and after injection with LPS (10 ng/mL) + IFN-γ (20 ng/mL), LPS (10 ng/mL) + IFN-γ (20 ng/mL) + CA2-2 (0.01 µM), and CA2-2 (0.01 µM or 0.05 µM)-treated macrophages. Data are presented as mean ± SE (n = 3). **p < 0.01, ***p < 0.001 compared to control